178 related articles for article (PubMed ID: 27995250)
21. Zoning in on Tankyrases: A Brief Review on the Past, Present and Prospective Studies.
Peters XQ; Malinga TH; Agoni C; Olotu FA; Soliman MES
Anticancer Agents Med Chem; 2019; 19(16):1920-1934. PubMed ID: 31648650
[TBL] [Abstract][Full Text] [Related]
22. Tankyrase inhibition sensitizes cells to CDK4 blockade.
Foronda M; Tarumoto Y; Schatoff EM; Leach BI; Diaz BJ; Zimmerman J; Goswami S; Shusterman M; Vakoc CR; Dow LE
PLoS One; 2019; 14(12):e0226645. PubMed ID: 31891587
[TBL] [Abstract][Full Text] [Related]
23. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
24. Identification of novel phosphodiesterase-4D inhibitors prescreened by molecular dynamics-augmented modeling and validated by bioassay.
Li Z; Cai YH; Cheng YK; Lu X; Shao YX; Li X; Liu M; Liu P; Luo HB
J Chem Inf Model; 2013 Apr; 53(4):972-81. PubMed ID: 23517293
[TBL] [Abstract][Full Text] [Related]
25. Structural basis of selective inhibition of human tankyrases.
Narwal M; Venkannagari H; Lehtiö L
J Med Chem; 2012 Feb; 55(3):1360-7. PubMed ID: 22233320
[TBL] [Abstract][Full Text] [Related]
26. Virtual screening of small molecules databases for discovery of novel PARP-1 inhibitors: combination of in silico and in vitro studies.
Ekhteiari Salmas R; Unlu A; Bektaş M; Yurtsever M; Mestanoglu M; Durdagi S
J Biomol Struct Dyn; 2017 Jul; 35(9):1899-1915. PubMed ID: 27315035
[TBL] [Abstract][Full Text] [Related]
27. Multiple receptor-ligand based pharmacophore modeling and molecular docking to screen the selective inhibitors of matrix metalloproteinase-9 from natural products.
Gao Q; Wang Y; Hou J; Yao Q; Zhang J
J Comput Aided Mol Des; 2017 Jul; 31(7):625-641. PubMed ID: 28623487
[TBL] [Abstract][Full Text] [Related]
28. Molecular dynamics-based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds.
Li Z; Lu X; Feng LJ; Gu Y; Li X; Wu Y; Luo HB
Mol Biosyst; 2015 Jan; 11(1):115-25. PubMed ID: 25328054
[TBL] [Abstract][Full Text] [Related]
29. [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.
Shultz MD; Kirby CA; Stams T; Chin DN; Blank J; Charlat O; Cheng H; Cheung A; Cong F; Feng Y; Fortin PD; Hood T; Tyagi V; Xu M; Zhang B; Shao W
J Med Chem; 2012 Feb; 55(3):1127-36. PubMed ID: 22260203
[TBL] [Abstract][Full Text] [Related]
30. Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases.
Lakshmi TV; Bale S; Khurana A; Godugu C
Curr Drug Targets; 2017; 18(10):1214-1224. PubMed ID: 27425647
[TBL] [Abstract][Full Text] [Related]
31. The binding mechanism of a novel nicotinamide isostere inhibiting with TNKSs: a molecular dynamic simulation and binding free energy calculation.
Feng TT; Zhang YJ; Chen H; Fan S; Han JG
J Biomol Struct Dyn; 2016; 34(3):517-28. PubMed ID: 25933061
[TBL] [Abstract][Full Text] [Related]
32. Probing PARP1-inhibitor complexes for the development of novel inhibitors.
Saqib U; Baig MS
Cell Mol Biol (Noisy-le-grand); 2014 Oct; 60(3):43-52. PubMed ID: 25346248
[TBL] [Abstract][Full Text] [Related]
33. Unravelling the Structural Mechanism of Action of 5-methyl-5-[4-(4-oxo-3H-quinazolin-2-yl)phenyl]imidazolidine-2,4-dione in Dual-Targeting Tankyrase 1 and 2: A Novel Avenue in Cancer Therapy.
Peters XQ; Agoni C; Soliman MES
Cell Biochem Biophys; 2022 Sep; 80(3):505-518. PubMed ID: 35637423
[TBL] [Abstract][Full Text] [Related]
34. Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening.
Sindhu T; Srinivasan P
Mol Biosyst; 2015 May; 11(5):1305-18. PubMed ID: 25787676
[TBL] [Abstract][Full Text] [Related]
35. Fragment-based ligand design of novel potent inhibitors of tankyrases.
Larsson EA; Jansson A; Ng FM; Then SW; Panicker R; Liu B; Sangthongpitag K; Pendharkar V; Tai SJ; Hill J; Dan C; Ho SY; Cheong WW; Poulsen A; Blanchard S; Lin GR; Alam J; Keller TH; Nordlund P
J Med Chem; 2013 Jun; 56(11):4497-508. PubMed ID: 23672613
[TBL] [Abstract][Full Text] [Related]
36. Insights of tankyrases: A novel target for drug discovery.
Damale MG; Pathan SK; Shinde DB; Patil RH; Arote RB; Sangshetti JN
Eur J Med Chem; 2020 Dec; 207():112712. PubMed ID: 32877803
[TBL] [Abstract][Full Text] [Related]
37. Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
Shirai F; Tsumura T; Yashiroda Y; Yuki H; Niwa H; Sato S; Chikada T; Koda Y; Washizuka K; Yoshimoto N; Abe M; Onuki T; Mazaki Y; Hirama C; Fukami T; Watanabe H; Honma T; Umehara T; Shirouzu M; Okue M; Kano Y; Watanabe T; Kitamura K; Shitara E; Muramatsu Y; Yoshida H; Mizutani A; Seimiya H; Yoshida M; Koyama H
J Med Chem; 2019 Apr; 62(7):3407-3427. PubMed ID: 30883102
[TBL] [Abstract][Full Text] [Related]
38. Identification of InhA inhibitors: A combination of virtual screening, molecular dynamics simulations and quantum chemical studies.
Lone MY; Manhas A; Athar M; Jha PC
J Biomol Struct Dyn; 2018 Aug; 36(11):2951-2965. PubMed ID: 28849732
[TBL] [Abstract][Full Text] [Related]
39. Discovery of a Novel Series of Tankyrase Inhibitors by a Hybridization Approach.
Anumala UR; Waaler J; Nkizinkiko Y; Ignatev A; Lazarow K; Lindemann P; Olsen PA; Murthy S; Obaji E; Majouga AG; Leonov S; von Kries JP; Lehtiö L; Krauss S; Nazaré M
J Med Chem; 2017 Dec; 60(24):10013-10025. PubMed ID: 29155568
[TBL] [Abstract][Full Text] [Related]
40. Molecular dynamics and integrated pharmacophore-based identification of dual [Formula: see text] inhibitors.
Kaur M; Singh PK; Singh M; Bahadur R; Silakari O
Mol Divers; 2018 Feb; 22(1):95-112. PubMed ID: 29138965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
